Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Ajer Jeffrey Robert
 2. Date of Event Requiring Statement (Month/Day/Year)
09/05/2012		 3. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]
(Last)
(First)
(Middle)
C/O BIOMARIN PHARMACEUTICAL INC.,, 105 DIGITAL DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Chief Commercial Of
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NOVATO, CA 94949		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 10,570
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) 11/22/2008(1) 05/21/2018 Common Stock 28,000 $ 38.59 D  
Stock Option (right to buy) 05/17/2009(2) 05/11/2019 Common Stock 1,000 $ 17.86 D  
Stock Option (right to buy) 11/12/2009(3) 05/11/2019 Common Stock 6,250 $ 14.39 D  
Stock Option (right to buy) 11/12/2010(4) 05/11/2020 Common Stock 30,000 $ 21.51 D  
Stock Option (right to buy) 11/08/2012(5) 05/11/2022 Common Stock 13,000 $ 37.46 D  
Stock Option (right to buy) 12/01/2011(6) 05/30/2021 Common Stock 23,700 $ 28.23 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Ajer Jeffrey Robert
C/O BIOMARIN PHARMACEUTICAL INC.,
105 DIGITAL DRIVE
NOVATO, CA 94949		       SVP, Chief Commercial Of  

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact 09/14/2012
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Original option grant vests 6/48th on November 22, 2008 and 1/48th on the 22nd of each month thereafter.
(2) Original option grant vests 6/48th on May 17, 2009 and 1/48th on the 17th of each month thereafter.
(3) Original option grant vests 6/48th on November 12, 2009 and 1/48th on the 12th of each month thereafter.
(4) Original option grant vests 6/48th on November 12, 2010 and 1/48th on the 12th of each month thereafter.
(5) Original option grant vests 6/48th on November 8, 2012 and 1/48th on the 8th of each month thereafter.
(6) Original option grant vests 6/48th on December 1, 2011 and 1/48th on the 1st of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.